Trial Profile

An Open-Label Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of BMB-101 in Adults With Either Classic Absence Epilepsy (With or Without Eyelid Myoclonia (EEM; Jeavons Syndrome), OR Developmental Epileptic Encephalopathy (DEE).

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 May 2025 According to Bright Minds Biosciences media release, Members of Bright Minds leadership team will review the therapeutic rationale for BMB-101 and discuss the BREAKTHROUGH study in its virtual R&D Day on Tuesday, May 20, 2025, from 10:00 am-11:30 am ET.
28 Apr 2025 According to Bright Minds Biosciences media release, The company will host a Key Opinion Leaders presentation on 20th May 2025 ,which will include an overview of the BREAKTHROUGH study.
12 Dec 2024 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com